Methods of treating vitiligo using PD-1 binding antibodies
AssigneeCelgene Corporation
InventorGarth E. Ringheim
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
Claims66
A method of managing or treating vitiligo in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to PD-1, wherein the antibody or antigen-binding fragment comprises:
- a light chain variable region (VL) comprising:
- a VL complementarity determining region 1 (CDR1) comprising SEQ ID NO:1,
- a VL CDR2 comprising SEQ ID NO:2, and
- a VL CDR3 comprising SEQ ID NO:3;
- and
- a heavy chain variable region (VH) comprising:
- a VH CDR1 comprising SEQ ID NO:4,
- a VH CDR2 comprising SEQ ID NO:5, and
- a VH CDR3 comprising SEQ ID NO:6.
The method of 1, wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.
The method of 9, wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.
Dependencies are inferred from the claim text.